Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | NQO1 | P15559 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.36 |
| ▸ | TUBB | P07437 | 2/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22408291 | 0.87 | KDM4E (0.44) | KDM4EHPGDIDO1TDO2TRPA1 | |
| SCHEMBL15450950 | 0.85 | KDM4E (0.56) | KDM4EHPGDNQO2CYP19A1NQO1 | |
| SCHEMBL21886096 | 0.82 | HRH4 (0.40) | KDM4EHPGDIDO1TDO2TRPA1 | |
| SCHEMBL22408526 | 0.81 | KDM4E (0.45) | KDM4EHPGDNQO2CYP19A1NQO1 | |
| SCHEMBL22408241 | 0.81 | IDO1 (0.41) | KDM4EIDO1TDO2TRPA1 | |
| SCHEMBL24136190 | 0.81 | HPGD (0.41) | KDM4EHPGDIDO1TDO2NQO2 | |
| SCHEMBL15704969 | 0.79 | PDE3B (0.35) | IDO1TDO2TRPA1NQO2CYP19A1 | |
| SCHEMBL7004139 | 0.79 | KDM4E (0.42) | KDM4EHPGDNQO2CYP19A1NQO1 | |
| SCHEMBL22408064 | 0.79 | HPGD (0.42) | KDM4EHPGDNQO2CYP19A1NQO1 | |
| SCHEMBL22408131 | 0.79 | PDE3B (0.35) | KDM4EHPGDTRPA1NQO2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3377483-B9 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-03 | — | — | EP | disclosed |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3928836-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-12-29 | — | — | EP | disclosed |
| EP-3928836-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-12-29 | — | — | EP | disclosed |
| WO-2021060281-A1 | PROSTAGLANDIN E2 RECEPTOR EP2/EP4 DUAL ANTAGONIST | ＡＧＣ株式会社 | 2021-04-01 | — | — | WO | disclosed |
| CN-108349949-B | N-substituted indole derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | KDM4E 2755/4885HPGD 178/4885IDO1 51/4885 |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | KDM4E 2755/4885HPGD 178/4885IDO1 51/4885 |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KDM4E 2755/4885HPGD 178/4885IDO1 51/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KDM4E 2755/4885HPGD 178/4885IDO1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.